ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference

By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provi...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bacco, Francesca, Boccaccio, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632286/
https://www.ncbi.nlm.nih.gov/pubmed/34859149
http://dx.doi.org/10.1080/23723556.2021.1990677
Descripción
Sumario:By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.

Ejemplares similares